News Sentiment

TTRX sentiment intelligence

Turn Therapeutics Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 60 Balanced news tone 62 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 5.87 Week of 19 Jun 2026
Weighted tone 60/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

77/100 classification confidence.

Company focus 55

directly relevant articles

Source quality 4

high-authority source matches

Trend context Trend active

-2.9% over one week, +14.4% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Turn Therapeutics Ord Shs (TTRX) Institutional Confidence

Market Reaction

Balanced read

69/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 77/100 classification
One-week reaction -2.9% Price reacting lower
Trend fit Trend active 14.4% over four weeks
Fair value 40.2% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 24
Neutral 36
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 55
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
TradingKey 9
Market source 6
TradingView 5
MarketBeat 4
Business Wire 3
simplywall.st 3
Stocktwits 2
Stock Titan 2

Event Lens

What the news is about

Classified themes
Market update 29
Earnings 22
Regulatory and legal 7
Analyst action 2
Guidance 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 62
TradingView Direct company coverage

Number of shareholders of Turn Therapeutics Inc. – NASDAQ:TTRX

The article provides information about Turn Therapeutics Inc. (NASDAQ: TTRX), focusing specifically on the number of shareholders. It indicates that further details on the shareholder count are available within the financial data section but doesn't list the exact numbers directl

Tone
Neutral 50/100
Event
Market update
Published
15 Jun 2026 12:09
Source
TradingView
TradingView Direct company coverage

Turn Therapeutics posts positive GX-03 Phase 2 interim results, updates investor presentation

Turn Therapeutics (TTRX) announced positive interim Phase 2 results for its topical drug GX-03, showing significant improvement in EASI scores for eczema and a favorable safety profile. The company also provided an updated investor presentation, detailing a development plan targe

Tone
Positive 80/100
Event
Earnings
Published
03 Jun 2026 10:09
Source
TradingView
Stock Titan Direct company coverage

Turn Therapeutics (NASDAQ: TTRX) details GX-03 interim data, onychomycosis plans and runway

Turn Therapeutics provided an updated investor presentation detailing its dermatology pipeline, including the lead asset GX-03. The presentation highlighted positive interim Phase 2 data for GX-03 in moderate to severe atopic dermatitis, showing significant reductions in EASI sco

Tone
Positive 67/100
Event
Market update
Published
03 Jun 2026 10:09
Source
Stock Titan
Financial Times Direct company coverage

Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis – Company Announcement - FT.com

Turn Therapeutics announced positive interim analysis findings from its Phase 2 GX-03 trial for moderate-to-severe atopic dermatitis, with significant reductions in eczema severity observed. The company is using these findings to optimize the trial's second stage, including refin

Tone
Positive 92/100
Event
Market update
Published
02 Jun 2026 09:09
Source
Financial Times
RTTNews Direct company coverage

Top Biotech Gainers: TTRX Turns Heads, LIXT Shifts To AI Energy, CNXU Update, QTRX, TRAX On Watch

This article highlights several top biotech gainers from Monday's trading. Turn Therapeutics Inc. (TTRX) saw its stock rise over 20% after reporting positive interim analysis findings for its atopic dermatitis study, while Conexeu Sciences Inc. (CNXU) gained over 18% due to progr

Tone
Positive 74/100
Event
Market update
Published
02 Jun 2026 02:39
Source
RTTNews
Moomoo Direct company coverage

Turn Therapeutics Shares Higher on Favorable Interim Eczema Drug Results

Turn Therapeutics Corporation announced positive interim results from its Phase 2a clinical trial for RevMya, a topical treatment for mild to moderate atopic dermatitis (eczema). The company reported significant improvements in eczema area and severity, alongside reductions in it

Tone
Neutral 50/100
Event
Earnings
Published
01 Jun 2026 23:39
Source
Moomoo
Investing.com UK Direct company coverage

Turn Therapeutics reports interim phase 2 data for eczema drug

Turn Therapeutics Inc. announced positive interim Phase 2 results for its eczema drug, GX-03, showing significant reductions in eczema severity. The positive data has contributed to a nearly 49% stock increase over the past six months. The company plans to use these findings to o

Tone
Positive 73/100
Event
Earnings
Published
01 Jun 2026 19:09
Source
Investing.com UK
TradingView Direct company coverage

Turn Therapeutics interim Phase 2 analysis shows rapid, deep EASI responses and favorable safety for GX-03

Turn Therapeutics reported positive interim results from its Phase 2 GX-03 trial for eczema. The analysis showed rapid and deep EASI responses, with 92.6% of patients achieving EASI-50 at four weeks, and favorable safety with no serious adverse events. The company plans to refine

Tone
Positive 91/100
Event
Earnings
Published
01 Jun 2026 13:09
Source
TradingView
Investing.com UK Direct company coverage

Turn Therapeutics publishes GX-03 dermatitis study results

Turn Therapeutics Inc. published study results showing its experimental treatment GX-03 significantly reduced dermatitis severity in a mouse model. This research highlights GX-03's potential as a topical therapy targeting inflammatory pathways in moderate-to-severe atopic dermati

Tone
Positive 80/100
Event
Earnings
Published
27 May 2026 19:08
Source
Investing.com UK
Investing.com Australia Direct company coverage

Turn Therapeutics publishes GX-03 dermatitis study results By Investing.com

Turn Therapeutics (NASDAQ:TTRX) announced the publication of research demonstrating that its experimental treatment, GX-03, significantly reduced dermatitis severity in a mouse model. The study, published in the Journal of Dermatological Treatment, showed a mean investigator glob

Tone
Positive 81/100
Event
Earnings
Published
27 May 2026 12:39
Source
Investing.com Australia
Business Wire Direct company coverage

Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model

Turn Therapeutics announced a peer-reviewed publication in the Journal of Dermatological Treatment, detailing the efficacy of its lead program, GX-03, in an IL-36 associated inflammatory model. The study demonstrated a statistically significant reduction in disease severity in a

Tone
Positive 75/100
Event
Market update
Published
27 May 2026 11:39
Source
Business Wire
PharmiWeb.com Direct company coverage

Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026

Turn Therapeutics Inc. will present at the Jefferies Global Healthcare Conference on June 4, 2026, where CEO Bradley Burnam will discuss the company's clinical-stage biotechnology and its lead investigational therapy, GX-03. GX-03 is a topical inhibitor for moderate-to-severe ato

Tone
Positive 63/100
Event
Regulatory and legal
Published
19 May 2026 14:39
Source
PharmiWeb.com
TipRanks Direct company coverage

Turn Therapeutics CEO to Present at Jefferies Conference

Turn Therapeutics Inc. (TTRX) CEO Bradley Burnam will present at the Jefferies Global Healthcare Conference on June 4, 2026. The presentation will be webcast live and available for replay, offering broad access to investors. TipRanks' AI Analyst, Spark, rates TTRX as Neutral due

Tone
Neutral 50/100
Event
Analyst action
Published
19 May 2026 13:10
Source
TipRanks
TradingView Direct company coverage

Turn Therapeutics to Present at Jefferies Global Healthcare Conference June 4

Turn Therapeutics announced that CEO Bradley Burnam will present at the Jefferies Global Healthcare Conference on June 4, 2026. He will provide an update on the company's clinical-stage biotech work, including its topical inhibitor GX-03 for atopic dermatitis, which is currently

Tone
Positive 61/100
Event
Market update
Published
19 May 2026 12:10
Source
TradingView
Minichart Direct company coverage

Turn Therapeutics Appoints Former FDA Commissioner Dr. Stephen Hahn to Lead Clinical and Regulatory Strategy for GX-03 Atopic Dermatitis Therapy 1

Turn Therapeutics has appointed Dr. Stephen M. Hahn, former FDA Commissioner, as its Executive Clinical and Regulatory Lead to guide the clinical and regulatory strategy for its lead investigational therapy, GX-03, for atopic dermatitis. Dr. Hahn brings extensive experience from

Tone
Positive 74/100
Event
Regulatory and legal
Published
18 May 2026 16:09
Source
Minichart
TipRanks Direct company coverage

Turn Therapeutics Appoints Former FDA Chief to Lead GX-03

Turn Therapeutics, a clinical-stage biotechnology company, has appointed former FDA Commissioner Stephen M. Hahn, M.D., to lead the clinical and regulatory strategy for its investigational therapy, GX-03. GX-03, a topical inhibitor for moderate-to-severe atopic dermatitis, is cur

Tone
Neutral 50/100
Event
Regulatory and legal
Published
18 May 2026 15:09
Source
TipRanks
citybiz Direct company coverage

Turn Therapeutics Recruits Former FDA Commissioner Stephen Hahn to Guide Eczema Drug Development

Turn Therapeutics has appointed former FDA Commissioner Dr. Stephen M. Hahn to lead the clinical and regulatory strategy for GX-03, its investigational therapy for moderate-to-severe atopic dermatitis. This move aims to strengthen the company's position in the competitive immunol

Tone
Positive 81/100
Event
Regulatory and legal
Published
18 May 2026 14:09
Source
citybiz
Investing.com Direct company coverage

Turn Therapeutics appoints former FDA chief Stephen Hahn

Turn Therapeutics Inc. has appointed Stephen M. Hahn, former FDA Commissioner, to head the clinical and regulatory strategy for its investigational topical therapy GX-03, currently in a Phase 2 trial for atopic dermatitis. The company, with a $121 million market cap, anticipates

Tone
Neutral 50/100
Event
Regulatory and legal
Published
18 May 2026 13:09
Source
Investing.com
Investing.com Canada Direct company coverage

Turn Therapeutics appoints former FDA chief Stephen Hahn By Investing.com

Turn Therapeutics has appointed Stephen M. Hahn, former FDA Commissioner, to head its clinical and regulatory strategy for its investigational topical therapy GX-03. The therapy is in Phase 2 trials for atopic dermatitis, with results expected mid-2026. The company recently secur

Tone
Positive 86/100
Event
Regulatory and legal
Published
18 May 2026 12:09
Source
Investing.com Canada